MediciNova (MNOV) Reports Positive Preliminary Results from Phase II Clinical Trial of MN-221

September 9, 2008 7:44 AM EDT

MediciNova, Inc. (Nasdaq: MNOV) reported positive preliminary results from a Phase II clinical trial evaluating MN-221 in patients with moderate to severe, stable asthma. This is one of two Phase II clinical trials being conducted to evaluate MN-221 in various populations of asthma patients. This clinical trial provided information on prolonged infusion dosing regimens with MN-221, and the preliminary results demonstrated clinically significant improvements in forced expiratory volume in one second (FEV1).

"We continue to be very encouraged by the data derived from the various clinical trials evaluating MN-221 completed to date," said Yuichi Iwaki, M.D., Ph.D., President and Chief Executive Officer of MediciNova, Inc.

MediciNova, Inc. is a publicly-traded biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet need with a specific focus on the U.S. market.

Related Categories

Corporate News
FDA

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?